ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 881 • 2015 ACR/ARHP Annual Meeting

    ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis

    Shoichi Fukui1, Naoki Iwamoto2, Masataka Umeda2, Ayako Nishino2, Yoshikazu Nakashima2, Tomohiro Koga2, Shin-ya Kawashiri2, Kunihiro Ichinose2, Yasuko Hirai1, Mami Tamai3, Hideki Nakamura1, Tomoki Origuchi4 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 3Transitional Med/Immun/Rheum, Nagasaki University, Nagasaki, Japan, 4Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan

    Background/Purpose: ANCA associated vasculitis (AAV) is known as a systemic vasculitis with unknown etiology. Recently, relationship between AAV and complement have been shown and complement…
  • Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting

    Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis

    Joanna Robson1, Susan Ashdown2, Jill Dawson3, Ebony Easley4, Don Gebhart5, Katherine Kellom6, Georgia Lanier7, Nataliya Milman8, Jacqueline Peck9, Judy A. Shea10, Peter F. Cronholm4 and Peter A. Merkel11, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 2NONE, Branbury, United Kingdom, 3Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, 4Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, 5NONE, Columbus, OH, 6PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, 7NONE, Framingham, MA, 8Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 9NONE, Oxford, United Kingdom, 10Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, 11Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
  • Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting

    Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis

    Sophia Lionaki1, George Fragoulis2, Aliki Venetsanopoulou2, Panayiotis Vlachoyiannopoulos2, John Boletis1, Haralampos M. Moutsopoulos2 and Athanasios G. Tzioufas2, 1Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, 2Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

    Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…
  • Abstract Number: 887 • 2015 ACR/ARHP Annual Meeting

    Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients

    Etienne Crickx1, Irène Machelart2, Estibaliz Lazaro3, Jean-Emmanuel Kahn4, Fleur Cohen5, Thierry Martin6, Alexandre Mania7, Pierre-Yves Hatron8, Gilles Hayem9, Claire Blanchard-Delaunay10, Claire De Moreuil11, Guillaume Le Guenno12, Frédéric Vandergheynst13, Francois Maurier14, Bruno Crestani15, Robin Dhote16, Nicolas Martin Silva17, Yann Ollivier18, Anas Mehdaoui19, Bertrand Godeau20, Xavier Mariette21, Jacques Cadranel22, Pascal Cohen23, Xavier Puéchal23, Claire Le Jeunne24, Luc Mouthon25, Loïc Guillevin26 and Benjamin Terrier23, 1Internal Medicine, Cochin Hospital, Paris, France, 2Hôpital Pellegrin, Pessac, France, 3Hôpital Haut-Lévêque, Pessac, France, 4Internal Medicine, Foch Hospital, Suresnes, France, 5Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, 6Cnrs UPR9021, IBMC, Strasbourg, France, 7Hôpital Gabriel Montpied, Clermont-Ferrand, France, 8Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, 9Hôpital Ambroise Paré, Boulogne Billancourt, France, 10Internal Medicine, Centre Hospitalier, Niort, France, 11CHU, Brest, France, 12Internal Medicine department, Clermont-Ferrand, France, 13Hôpital Erasme, Bruxelles, Belgium, 14HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 15Pneumology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, 16Internal Medicine, Hospital Avicenne, Bobigny, France, 17CHU Caen, caen, France, 18Hôpital Cote de Nacre, Caen, France, 19Hôpital Eure Seine, Evreux, France, 20Henri Mondor, Créteil, France, 21Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 22Hôpital Tenon, Paris, France, 23Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 24Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, 25Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, 26Internal Medicine, Hopital Cochin, Paris, France

    Background/Purpose: Despite recent therapeutic advances in treating ANCA-associated vasculitides (AAVs), some patients relapse or require long-term immunosuppression, leading to significant morbidity and mortality. IVIg represents…
  • Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting

    Peripheral CD5+ b-Cells in ANCA-Associated Vasculitis

    Sebastian Unizony1, Noha Lim2, Vincent Carey3, Deborah J. Phippard2, Nadia Tchao2, Eli M. Miloslavsky4, Peter A. Merkel5, Paul Monach6, William St. Clair7, Robert F. Spiera8, Adam Asare2, Philip Seo9, Carol A. Langford10, Gary S. Hoffman11, Cees Kallenberg12, Ulrich Specks13 and John H. Stone4, 1Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Immune Tolerance Network, Bethesda, MD, 3Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Massachusetts General Hospital, Boston, MA, 5Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 6Rheumatology, Boston University, Boston, MA, 7Rheumatology and Immunology, Duke University, Durham, NC, 8Rheumatology, Hospital for Special Surgery, New York, NY, 9Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 10Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 11Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, 12Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, 13Frederichs Dr NW, Mayo Clinic, Rochester, MN

    Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV)   Methods CD5+ B-cells were measured longitudinally by…
  • Abstract Number: 1764 • 2014 ACR/ARHP Annual Meeting

    Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis

    Santhi Penmetsa1, N. Suzanne Emil2, Joshua Duchesne1, Wilmer Sibbitt Jr.3, Arthur Bankhurst4 and Roderick Fields5, 1Rheumatology, University of New Mexico Health sciences center, Albuquerque, NM, 2Rheumatology, Presbyterian Medical Group, Rio Rancho, NM, 3Rheumatology, University of New mexico health sciences center, Albuquerque, NM, 4Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, 5Division of Rheumatology, University of New Mexico health Sciences center, Albuquerque, NM

    Background/Purpose Objective: To compare various factors including clinical manifestations, laboratory data and mortality in between two groups of patients with anti-neutrophil cytoplasmic antibody (ANCA) positive…
  • Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting

    Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature

    Alice Sy1, Natasha Dehghan2, Nader A. Khalidi3, Lillian Barra4, Simon Carette5, David Cuthbertson6, Gary S. Hoffman7, Curry L Koening8, Carol A. Langford9, Carol McAlear10, Paul A. Monach11, Larry W. Moreland12, Philip Seo13, Ulrich Specks14, Steven R. Ytterberg15, Gert Van Assche16, Peter A. Merkel10 and Christian Pagnoux5, 1Medicine Division, London, ON, Canada, 2Rheumatology Division, Vancouver, BC, Canada, 3Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 4Rheumatology, St. Joseph's Health Care, London, ON, Canada, 5Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 6Department of Biostatistics, University of South Florida, Tampa, FL, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 9Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 10University of Pennsylvania, Philadelphia, PA, 11Rheumatology, Boston University, Boston, MA, 12Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 13Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, 14Mayo Clinic, Rochester, MN, 15Rheumatology Division, Mayo Clinic, Rochester, MN, 16Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose:  Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…
  • Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting

    Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)

    Kimberly Morishita1, Susanne Benseler2, Rae S.M. Yeung3, Thomas Mason II4, Dawn Wahezi5, Kenneth N. Schikler6, Erica F. Lawson7, Susan Nielsen8, Sirirat Charuvanij9, Paul Dancey10, Susan Shenoi11, Linda Wagner-Weiner12, Angelyne Sarmiento1, David A. Cabral13 and For the PedVas Initiative1, 1BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 2Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, 3Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 4Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, 5Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, 6Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, 7Pediatrics, University of California, San Francisco, San Francisco, CA, 8Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, 9Pediatrics, Siriraj Hospital, Bangkok, Thailand, 10Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, 11Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, 12Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, 13Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose:  Childhood AAV is rare and outcome studies are limited.  The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
  • Abstract Number: 85 • 2014 ACR/ARHP Annual Meeting

    Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population

    Naoyuki Tsuchiya1, Narumi Hasebe1, Ken-ei Sada2, Shigeto Kobayashi3, Hidehiro Yamada4, Hiroshi Furukawa5, Kunihiro Yamagata6, Takayuki Sumida7, Nobuyuki Miyasaka8, Seiichi Matsuo9, Shigeto Tohma5, Shoichi Ozaki10, Hiroshi Hashimoto11, Hirofumi Makino2, Masayoshi Harigai12 and Aya Kawasaki1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 6Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 7Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 8Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 9Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 10Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 11Juntendo University School of Medicine, Tokyo, Japan, 12Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority…
  • Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting

    Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis

    Amanda Schlefman1, Maureen Leffler2, AnneMarie C. Brescia3 and Carlos D. Rose4, 1A.I. DuPont Hospital for Children, Wilmington, DE, 2Rheumatology, AI duPont Hospital for Children, Wilmington, DE, 3Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, 4Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE

    Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…
  • Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting

    Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies

    Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…
  • Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting

    CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Pirow Bekker1, David Jayne2, Annette Bruchfeld3, Matthias Schaier4, Kazimierz Ciechanowski5, Lorraine Harper6, Michel Jadoul7, Mårten Segelmark8, Daina Selga9, Istvan Szombati10, Michael Venning11, Christian Hugo12, Paul L. van Daele13, Ondrej Viklicky14, Antonia Potarca15 and Thomas J. Schall15, 1Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, 2Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 3Karolinska Institute, Stockholm, Sweden, 4University of Heidelberg, Heidelberg, Germany, 5Pomeranian Medical University, Szczecin, Poland, 6Nephrology, University of Birmingham, Birmingham, United Kingdom, 7Cliniques Saint-Luc, Brussels, Belgium, 8Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, 9Lund University, Lund, Sweden, 10Budaclinic, Budapest, Hungary, 11Manchester University, Manchester, United Kingdom, 12Dresden University, Dresden, Germany, 13Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 14Instit of Clin and Exp Med, Prague, Czech Republic, 15ChemoCentryx, Inc., Mountain View, CA

    Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
  • Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting

    The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis

    Peter C. Grayson1, Carmelo Carmona-Rivera1, Lijing Xu2, Noha Lim2, Adam Asare2, Deborah J. Phippard2, Mariana J. Kaplan3, Peter A. Merkel4 and Paul A. Monach5, 1NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 2Immune Tolerance Network, Bethesda, MD, 3Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4University of Pennsylvania, Philadelphia, PA, 5Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA

    Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
  • Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting

    Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis

    Boun Kim Tan1, Yoann Crabol1, Jason Tasse2,3, Frederic Laurent2,3, Xavier Puechal4,5, Christine Vinter6 and Loïc Guillevin1,5, 1Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, 2Laboratoire de Bactériologie de l'hôpital de la Croix-Rousse, National Reference Centre for Staphylococci, Lyon, France, 3INSERM U1111, CNRS UMR5308, International Centre for Research in Infectious Diseases, Lyon, France, 4Internal Medicine, Hôpital Cochin, Paris, France, 5French Vasculitis Study Group (FVSG), Paris, France, 6Internal Medecine, Hôpital Cochin, Paris, France

    Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…
  • Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting

    Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy

    Benjamin Terrier1, Christian Pagnoux2, Guillaume Geri3, Alexandre Karras4, Chahéra Khouatra5, Olivier Aumaitre6, Pascal Cohen7, Francois Maurier8, Olivier Decaux9, Hélène Desmurs-Clavel10, Pierre Gobert11, Thomas Quemeneur12, Claire Blanchard-Delaunay13, Pascal Godmer14, Xavier Puéchal7, Luc Mouthon7 and Loïc Guillevin for the French Vasculitis Study Group7, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 3Intensive Care Unit, Cochin Hospital, Paris, France, 4Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 5CHU Louis Pradel, Lyon, Lyon, France, 6Internal Medicine, CHU, Clermont-Ferrand, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 8HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 9Department of Internal Medicine, Rennes University Hospital, Rennes, France, 10University of Lyon, LYON, France, 11Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 12Internal Medicine, CH, Valenciennes, France, 13Internal Medicine, Hôpital de Niort, Niort, France, 14Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France

    Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology